Last reviewed · How we verify

NCT03872102

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

Recruiting now Last updated 27 January 2026
What this trial tests

trial in Parkinson Disease in 90 participants. Currently enrolling.

Timeline
28 March 2019
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorUniversity of Texas Southwestern Medical Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment90
Start date28 March 2019
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across United States

Conditions studied

Sponsor

University of Texas Southwestern Medical Center

Who can join

Eligibility, any sex, with Parkinson Disease or Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03872102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing